Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

1.2K
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
1.2K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

2.2K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
2.2K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

6.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.5K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

375
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
375

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucose Monitoring and Control Testing in Patients with Type 1 or Type 2 diabetes.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

Fundamentals of Diabetes Management.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2026
Same author

Smart Pens: Expectations Regarding Use and Functionality From Health Care Providers.

Journal of diabetes science and technology·2026
Same author

Correction: Protection through early knowledge: clinical onset of type 1 diabetes in children and adolescents with and without early T1D detection programmes.

BMC pediatrics·2026
Same author

Screening Children for Early-Stage Type 1 Diabetes.

JAMA·2026
Same author

Diabetes Technology Across the Lifespan of People With Diabetes (Ages 2-88 Years): Insights From the dt-Report on Usage Trends Across all Age Groups.

Journal of diabetes science and technology·2026

Related Experiment Video

Updated: Apr 18, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K

Optimizing insulin pump therapy: the potential advantages of using a structured diabetes management program.

Karin Lange1, Ralph Ziegler, Andreas Neu

  • 1Department of Medical Psychology, Hannover Medical School , Hannover , Germany.

Current Medical Research and Opinion
|January 20, 2015
PubMed
Summary

Personalized Diabetes Management (PDM) optimizes continuous subcutaneous insulin infusion (CSII) therapy by enhancing patient-physician communication and self-management skills. This structured approach improves diabetes care despite workflow challenges.

Keywords:
AdherenceCSIIData managementPatient satisfactionPersonalizedSMBG

More Related Videos

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

2.9K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

2.0K

Related Experiment Videos

Last Updated: Apr 18, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.5K
Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
06:33

Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells

Published on: February 2, 2024

2.9K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

2.0K

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Diabetes Management

Background:

  • Continuous subcutaneous insulin infusion (CSII) therapy enhances glycemic control and treatment satisfaction in diabetes.
  • Patient and clinician factors can impede optimal CSII therapy effectiveness.
  • New strategies are needed to overcome obstacles in CSII therapy implementation.

Purpose of the Study:

  • To adapt the Personalized Diabetes Management (PDM) model for CSII-treated patients.
  • To implement a workflow structure that improves patient-physician communication.
  • To support diabetes self-management skills in patients using CSII therapy.

Main Methods:

  • Adapted Ceriello's PDM model for CSII therapy.
  • Developed a structured workflow to enhance patient-physician communication.
  • Focused on improving patients' diabetes self-management skills.

Main Results:

  • The PDM process can be systematically integrated into clinical practice.
  • Implementation requires workflow modification and learning PDM steps.
  • Invested time is expected to yield improved workflow and patient consultations.

Conclusions:

  • PDM offers a systematic, standardized process to optimize CSII therapy.
  • This approach enhances communication and self-management for CSII patients.
  • PDM implementation can overcome challenges in diabetes care.